COMMUNIQUÉS West-GlobeNewswire

Nicox : Prolongation de 5 ans de la durée d’un brevet américain couvrant le latanoprostene bunod commercialisé sous le nom de VYZULTA®
31/01/2024
Communiqué de presse Nicox : Prolongation de 5 ans de la durée d’un brevet américain couvrant le latanoprostène bunod commercialisé sous le nom de VYZULTA ® 31 janvier 2024 – diffusion à 7h30 Sophia Antipolis, France [...]
ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry
31/01/2024
ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry ANT-01 is in late-stage development as an adjunctive treatment for major depressive disorder ( [...]
Geneva Court Grants Temporary Moratorium to ObsEva
31/01/2024
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today [...]
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
31/01/2024
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and [...]
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
31/01/2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko ® approved for all indications of reference medicine Tyruko ® biosimilar to treat adults with highly active relapsing [...]
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
31/01/2024
Ad hoc announcement pursuant to Art. 53 LR Full year (continuing operations 2 ) Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD) Sales growth was mainly driven by continued strong [...]
Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
31/01/2024
Annonce événementielle au sens de l’art. 53 RC Exercice complet (activités poursuivies 2 ) Hausse de +10 % (tcc, +8 % USD) du chiffre d’affaires net et de +18 % (tcc, +11 % USD) du résultat opérationnel core La [...]
Vaxcyte Announces Pricing of $750 Million Public Offering
31/01/2024
SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]
Immunocore Prices Upsized Convertible Senior Notes Offering
31/01/2024
Immunocore Prices Upsized Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 30, 2024) Immunocore Holdings plc (Nasdaq: IMCR) today announced the pricing of $ [...]
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
31/01/2024
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company that [...]
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
31/01/2024
“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic [...]
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
31/01/2024
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter [...]
IBA SA – NOTIFICATION TRANSPARENCE
31/01/2024
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 31 janvier 2024, 01:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
IBA – TRANSPARENCY NOTIFICATION
31/01/2024
(Article 14, paragr aph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, January 31, 2024 01:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
Corbus Pharmaceuticals Announces Proposed Public Offering
31/01/2024
NORWOOD, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that it [...]
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc.
31/01/2024
HOUSTON, TEXAS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) announced today that it has signed an equity purchase agreement to sell its Activ Nutritional [...]
Trinity Biotech plc to Host Investor Call
30/01/2024
Conference Call Scheduled for Wednesday, January 31, 2024 at 8:30 AM ET DUBLIN, Ireland, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of [...]
Investors and Innovators Representing more than $309B in Biotech Assets and 624 New Drugs in Development Urge the Congressional Budget Office to Update its Drug R&D Policy Impact Model
30/01/2024
Letter responds to CBO’s call for input on how investors make decisions about funding research of new drugs WASHINGTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- More than 350 biotech investors, executives, and economists today [...]
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
30/01/2024
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and [...]

Pages